本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Viking Therapeutics, Inc.

32.10
+0.16000.50%
盘前32.220.1200+0.37%05:04 EDT
成交量:281.34万
成交额:9,000.12万
市值:36.05亿
市盈率:-27.83
高:32.59
开:32.10
低:31.63
收:31.94
数据加载中...
2025/07/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/07/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/07/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/05/27

重要事件披露

Form 8-K - Current report
2025/04/24

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/04/23

重要事件披露

Form 8-K - Current report
2025/04/23

重要事件披露

Form 8-K - Current report
2025/04/09

SEC问询函

Form CORRESP - Correspondence
2025/03/11

重要事件披露

Form 8-K - Current report
2025/02/26

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/05

重要事件披露

Form 8-K - Current report
2025/01/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/15

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/08

关联方拟减持公告

Form 144 | VIKING THERAPEUTICS, INC. 董事 Lawson Macartney 拟减持2000股,总价约13.73万美元
2024/11/04

重要事件披露

Form 8-K - Current report
2024/10/28

关联方拟减持公告

Form 144 | Viking Therapeutics高管Greg Zante拟减持131687股,总价约1028万美元
2024/10/25

关联方拟减持公告

Form 144 | Viking Therapeutics董事 Rouan Sarah Kathryn 拟减持11000股,总价约88.94万美元
2024/10/25

关联方拟减持公告

Form 144 | Viking Therapeutics董事 Singleton拟减持16000股,总价约127万美元